Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-828 in Healthy Subjects
NCT02817516Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-828 in Crohn's disease and inflammatory bowel disease (IBD) (8 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event at Day 24, Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event at Day 24 and 3 more. Started Jun 2016; status: terminated.
02
Drugs
TAK-828
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02817516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817516.